News
SPHRY
5.30
NaN%
--
Starpharma plans first-in-human Phase 1 trial of DEP HER2 radiotherapy in Europe
PUBT · 04/20 23:43
Rhuroin becomes Starpharma substantial holder with 9.52% stake
PUBT · 04/14 22:46
Radiopharm Theranostics Partners with Starpharma to Develop Novel Radiopharmaceutical Using DEP® Platform
Reuters · 09/30/2025 10:05
Starpharma Holdings Limited Announces Collaboration and License Agreement with Genentech for Cancer Therapy Development
Reuters · 09/22/2025 11:30
STARPHARMA ANNOUNCES A COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH
Reuters · 09/22/2025 11:30
Weekly Report: what happened at SPHRY last week (0908-0912)?
Weekly Report · 09/15/2025 11:00
Weekly Report: what happened at SPHRY last week (0901-0905)?
Weekly Report · 09/08/2025 11:02
Weekly Report: what happened at SPHRY last week (0825-0829)?
Weekly Report · 09/01/2025 10:58
STARPHARMA FY NET INCOME AUD -10 MILLION
Reuters · 08/26/2025 00:48
Weekly Report: what happened at SPHRY last week (0818-0822)?
Weekly Report · 08/25/2025 11:08
Weekly Report: what happened at SPHRY last week (0811-0815)?
Weekly Report · 08/18/2025 11:00
Weekly Report: what happened at SPHRY last week (0804-0808)?
Weekly Report · 08/11/2025 11:06
Weekly Report: what happened at SPHRY last week (0728-0801)?
Weekly Report · 08/04/2025 11:09
Weekly Report: what happened at SPHRY last week (0721-0725)?
Weekly Report · 07/28/2025 11:10
More
Webull provides a variety of real-time SPHRY stock news. You can receive the latest news about Starpharma Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SPHRY
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.